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Introduction
compounds, gliotoxin, also disrupted mature biofilms on its own (Figure 1c ). TPCK irreversibly 138 inhibits chymotrypsin (a serine peptidase) and can also inhibit some cysteine peptidases while 139 gliotoxin inhibits the chymotrypsin-like activity of the 20S proteasome. Acivicin, on the other 140 hand, is an inhibitor of gamma-glutamyl transpeptidase, an enzyme that transfers gamma-141 glutamyl groups from peptide donors to peptide acceptors as well as acting as a hydrolase to 142 remove gamma-glutamyl groups from peptides. None of the 25 aspartyl protease inhibitors tested 143 were able to disrupt mature C. albicans biofilms on their own, and only one of the 22 aspartyl 144 protease inhibitors tested, the HIV-1 protease inhibitor nelfinavir, was able to inhibit biofilm 145 formation on its own (BIC 50 µM) ( Figure 1d ).
146
Combination Screens 147 We tested whether any compounds from the three protease inhibitor libraries could Figure   152 2a). We did not observe any synergies with amphotericin B or caspofungin in this assay. Two of 153 these five compounds, gliotoxin and TPCK, were also "hits" in the stand-alone Sustained 154 Inhibition Biofilm Assay described above. The remaining three compounds, lisinopril, Z-Prolyl- Figure 2b ). Dec-RVKR-CMK, also known as furin convertase inhibitor, 163 inhibits the subtilisin (Kex2p-like) proprotein convertase (a type of serine protease). 164 We next evaluated 17 aspartyl protease inhibitors in the Sustained Inhibition Biofilm the presence of amphotericin B or fluconazole. We were surprised to find compounds that were 178 effective at disrupting mature biofilms, but were not effective at inhibiting biofilm formation, 179 namely atazanavir, indinavir, and API16. We also note that the macrocycle API19 had a is a relatively new concept, there is some precedent for this idea in bacterial biofilms, where 198 extracellular proteases were found to be involved in the processing of adhesion molecules during Sap6 for biofilm formation (45) and previous reports that aspartyl protease inhibitors affect C. 207 albicans in vitro and in vivo (47-60, 62), aspartyl protease inhibitors are potentially promising 208 combination treatments for C. albicans biofilm infections which are recalcitrant to single drug 209 treatments. We note, however, that we screened fewer inhibitors of other classes of proteases 210 than we did for aspartyl proteases. Despite this bias, we succeeded in identifying several 211 inhibitors of two additional classes of proteases, serine and metalloproteases. It may prove 212 rewarding to conduct additional screens of FDA-approved drugs whose mechanisms rely on the 213 inhibition of other classes of proteases with the goal of repurposing these drugs as novel 214 antifungals.
215
Perhaps the most unexpected result from this study was the identification of compounds 216 capable of disrupting mature biofilms that were unable to prevent biofilm formation ( Figure 5 ).
217
Unlike the opposite case, where a compound that could prevent biofilm formation might be 218 unable to penetrate a mature biofilm to have an effect, it is not readily apparent how the capacity 219 to disrupt an established biofilm would not also inhibit the formation of a biofilm. Although we 220 do not understand the basis for this result, it demonstrates that compounds that disrupt biofilms 221 are not simply a subset of those that inhibit formation ( Figure 5 ). This observation underscores 222 the importance of screening compounds for their antibiofilm capabilities in both types of assays.
223
Although we focused on one type of compound, protease inhibitors, this study raises 224 several points to consider when screening for antibiofilm agents. First, consistent with previous 225 reports (43, 44), our results highlight the importance of screening for synergistic interactions, as 226 we detected more hits and hits with stronger effects against biofilms when existing antifungal 227 agents were present along with the compound of interest ( Figure 5 ). Second, our results highlight 228 the importance of screening using biofilms as opposed to planktonic cultures. For example, in 229 our biofilm assays with saquinavir, amphotericin B showed more synergy than fluconazole 230 whereas the opposite relationship was reported for planktonic cultures (63). We also note that we 231 identified compounds that had effects on their own but not in combination with existing 232 antifungal agents, as well as the reverse. As such, pursuing multiple assays (e.g. planktonic 233 versus biofilm, stand-alone compounds versus combinations) maximizes the chance of 234 identifying useful compounds. 235 Finally, we note that this study was largely inspired by the discovery of the biofilm All assays were performed using SNY425, a SC5314-derived prototrophic a/α strain (72).
249
C. albicans cells were cultured as previously described; in brief, cells were allowed to recover 250 from glycerol stocks for two days at 30°C on yeast extract peptone dextrose (YEPD) plates (2% 
304
We then determined whether each experimental repeat (1) had an average absorbance of less 305 than the average of the control wells and (2) was significant after the multiple comparisons 306 correction. To be considered a validated hit, a compound had to satisfy both of these criteria in 307 each repeat if it was tested twice, for at least two repeats if it was tested three times, and for at 308 least five repeats if it was tested six times. Data and statistics for the Stand-alone Sustained concentration that met these requirements for which all higher concentrations of the same 327 compound also met these requirements. If no concentration met these requirements, the BIC is 328 indicated as greater than the highest concentration tested for that compound. Data and statistics 329 for the BIC Sustained Inhibition Optical Density Biofilm Assay are compiled in File S2. Compounds and controls were tested in groups of eight wells and two distinct groups of 340 controls were included for all candidate compounds and antifungal agents tested on a given plate.
341
The first set of controls contained the candidate compound, but no antifungal agent, while the 342 second set of controls contained the antifungal agent, but no candidate compound. The 
